Literature DB >> 28877606

Discordance Between VASP Phosphorylation and Platelet Aggregation in Defining High On-Clopidogrel Platelet Reactivity After ST-Segment Elevation Myocardial Infarction.

Jing Sun1,2, Guo-Hong Yang1,2, Jun-Xiang Liu1, Xin-Lin Liu1, Yong-Qiang Ma1, Rui-Yi Lu1, Ying-Ying Zhang1, Shao-Bo Chen1, Ji-Hong Zhao1, Wen-Jie Ji1, Xin Zhou1, Yu-Ming Li1.   

Abstract

To investigate potential clinical characteristics associated with discordance between platelet vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry (FCM) assay and light transmission aggregometry (LTA) in defining high on-clopidogrel platelet reactivity (HPR) after ST-segment elevation myocardial infarction (STEMI). In this study, platelet responsiveness was measured by the above 2 methods simultaneously on day 1 and on day 6 of STEMI onset in 90 consecutive patients who underwent primary percutaneous coronary intervention. The FCM-derived platelet reactivity index and LTA-derived platelet aggregation rate were both significantly reduced after dual antiplatelet therapy on day 6. Multiple variable-adjusted logistic regression analysis revealed that smoking (odds ratio [OR]: 4.507, 95% confidence interval [CI]: 1.123-18.09, P = .034) and onset-to-admission time (per 1 hour increase, OR: 1.196, 95% CI: 1.023-1.398, P = .025) both were independent predictors for the discordance between the 2 methods. Additionally, improved correlation and concordance was observed in nonsmokers compared with smokers. Our data show that smoking and prolonged onset-to-admission time are associated with discordance between platelet VASP-P and LTA in defining HPR after STEMI, which should be considered when planning personalized antiplatelet therapy.

Entities:  

Keywords:  percutaneous coronary intervention; platelet reactivity index; platelet responsiveness

Mesh:

Substances:

Year:  2017        PMID: 28877606      PMCID: PMC6714637          DOI: 10.1177/1076029617726600

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  38 in total

1.  Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction.

Authors:  Young-Hoon Jeong; Jung-Hyun Cho; Min-Kyung Kang; Jin-Sin Koh; In-Suk Kim; Yongwhi Park; Seok-Jae Hwang; Choong Hwan Kwak; Jin-Yong Hwang
Journal:  Thromb Res       Date:  2010-05-06       Impact factor: 3.944

2.  High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.

Authors:  Nicoline J Breet; Jochem W van Werkum; Heleen J Bouman; Johannes C Kelder; Ankie M Harmsze; Christian M Hackeng; Jurriën M ten Berg
Journal:  Heart       Date:  2011-04-08       Impact factor: 5.994

3.  Composition of coronary thrombus in acute myocardial infarction.

Authors:  Johanne Silvain; Jean-Philippe Collet; Chandrasekaran Nagaswami; Farzin Beygui; Kathryn E Edmondson; Anne Bellemain-Appaix; Guillaume Cayla; Ana Pena; Delphine Brugier; Olivier Barthelemy; Gilles Montalescot; John W Weisel
Journal:  J Am Coll Cardiol       Date:  2011-03-22       Impact factor: 24.094

4.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Authors:  Laurent Bonello; Udaya S Tantry; Rossella Marcucci; Ruediger Blindt; Dominick J Angiolillo; Richard Becker; Deepak L Bhatt; Marco Cattaneo; Jean Philippe Collet; Thomas Cuisset; Christian Gachet; Gilles Montalescot; Lisa K Jennings; Dean Kereiakes; Dirk Sibbing; Dietmar Trenk; Jochem W Van Werkum; Franck Paganelli; Matthew J Price; Ron Waksman; Paul A Gurbel
Journal:  J Am Coll Cardiol       Date:  2010-09-14       Impact factor: 24.094

Review 5.  Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.

Authors:  Dániel Aradi; András Komócsi; András Vorobcsuk; Orsolya Rideg; Margit Tokés-Füzesi; Tamás Magyarlaki; Iván Gábor Horváth; Victor L Serebruany
Journal:  Am Heart J       Date:  2010-09       Impact factor: 4.749

6.  Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.

Authors:  Jeffrey S Berger; Deepak L Bhatt; Steven R Steinhubl; Mingyuan Shao; P Gabriel Steg; Gilles Montalescot; Werner Hacke; Keith A Fox; A Michael Lincoff; Eric J Topol; Peter B Berger
Journal:  Circulation       Date:  2009-11-23       Impact factor: 29.690

7.  Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events.

Authors:  L Bonello; F Paganelli; M Arpin-Bornet; P Auquier; J Sampol; F Dignat-George; P Barragan; L Camoin-Jau
Journal:  J Thromb Haemost       Date:  2007-05-07       Impact factor: 5.824

8.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.

Authors:  Lawrence Ang; Vachaspathi Palakodeti; Ahmer Khalid; Sotirios Tsimikas; Zaheib Idrees; Phillip Tran; Paul Clopton; Nayab Zafar; Guilherme Bromberg-Marin; Shahin Keramati; Ehtisham Mahmud
Journal:  J Am Coll Cardiol       Date:  2008-09-23       Impact factor: 24.094

10.  Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.

Authors:  Jolanta M Siller-Matula; Irene Lang; Guenter Christ; Bernd Jilma
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

View more
  1 in total

1.  Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.

Authors:  Jian-Qi Zhang; Guo-Hong Yang; Xin Zhou; Jun-Xiang Liu; Rui Shi; Yan Dong; Shao-Bo Chen; Yu-Ming Li
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.